Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsors and Collaborators: |
Bayside Health The Alfred Monash University |
---|---|
Information provided by: | Bayside Health |
ClinicalTrials.gov Identifier: | NCT00164021 |
Gastro-oesophageal reflux (GOR) has been found to be prevalent in children with cystic fibrosis (CF)and may further worsen lung damage via reflex bronchospasm or pulmonary aspiration. Chest physiotherapy may result in increased episodes of GOR as demonstrated in children. Lung transplantation may worsen pre-existing GOR. This study will determine the prevalence, severity and significance of symptomatic and silent GOR in adults with CF before and after lung transplant using 24hr oesophageal pH monitoring, a valid symptom questionnaire, quality of life questionnaires and gastric emptying studies.
This study will identify the extent of GOR in a large adult CF population and the impact on lung function and quality of life together with the effects of medical and physiotherapy treatment on gastro-oesophageal function.
Condition | Intervention |
---|---|
Cystic Fibrosis |
Procedure: Physiotherapy, exercise, percutaneous gastrostomy feeds Drug: Anti-reflux pharmacotherapy |
Study Type: | Observational |
Study Design: | Screening, Longitudinal, Defined Population, Prospective Study |
Official Title: | The Prevalence and Significance of Gastro-Oesophageal Reflux in Adults With Cystic Fibrosis Before and After Lung Transplantation, Together With the Effects of Physiotherapy Airway Clearance Techniques on Gastro-Oesophageal Function |
Estimated Enrollment: | 180 |
Study Start Date: | February 2001 |
A factorial longitudinal study will be undertaken in adults with cystic fibrosis. Results will be compared with age matched healthy controls. It is not deemed appropriate to randomise patients with gastro-oesophageal reflux(GOR) to a treatment versus no treatment group as immediate treatment for GOR once diagnosed is regarded as obligatory. Subjects: 180 adults with CF will be recruited from the Adult Cystic Fibrosis Unit at the Alfred Hospital to participate in the study. The ambulatory studies will be undertaken during baseline state in the outpatient setting. Fifteen age matched control subjects will be recruited from the general population.
Subjects who give their consent for participation in the study will undertake the following outcome measures:
Dual-channel 24hour oesophageal pH monitoring will be undertaken using a digitrapper (Medtronic, Sweden)and dual antimony tipped probe (Synectics, Sweden). Following calibration of the probes the distal antimony tip is positioned 5cm above the upper border of the lower oesophageal sphincter and the proximal probe 15 cm above the distal probe in the upper oesophagus.The patient will be instructed in using the three event buttons on the digitrapper recording start and finish time of meals, upright versus supine positioning and reflux episodes. The subject will be provided with a detailed 24hr 'Activity Diary' to record all meals (including percutaneous gastrostomy feeds), positions and activities including usual chest physiotherapy and physical exercise.The recorded pH information is downloaded into a computer program for analysis. The following indices will be measured in the distal and proximal oesophagus:
Ages Eligible for Study: | 16 Years to 70 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
* Diagnosis of cystic fibrosis
Exclusion Criteria:
Contact: Brenda M. Button, DPhty, PhD | 9276 2000 ext 3450 | b.button@alfred.org.au |
Australia, Victoria | |
The Alfred Hospital | Recruiting |
Melbourne, Victoria, Australia, 3004 | |
Contact: Brenda M Button, DPhty, PhD 9276 2000 ext 3450 b.button@alfred.org.au | |
Contact: John W Wilson, MBBS, PhD 9276 2000 ext 3600 john.wilson@med.monash.edu.au | |
Principal Investigator: Brenda M Button, DPhty,PhD | |
Sub-Investigator: Susannah King | |
Sub-Investigator: Colleen Ash | |
Sub-Investigator: John W Wilson, MBBS, PhD | |
Sub-Investigator: Greg Snell, MBBS | |
Sub-Investigator: Stuart Roberts, MBBS |
Principal Investigator: | Brenda M Button, DPhty, PhD | The Alfred Hospital, Melbourne |
Principal Investigator: | Susannah King | The Alfred Hospital, Melbourne |
Principal Investigator: | Colleen Ash | The Alfred Hospital, Melbourne |
Principal Investigator: | John W Wilson, MBBS, PhD | The Alfred Hospital, Melbourne |
Principal Investigator: | Greg Snell, MBBS | The Alfred Hospital, Melbourne |
Principal Investigator: | Stuart Roberts, MBBS | The Alfred |
Study ID Numbers: | 1/01, Alfred Hospital $20,000 grant |
Study First Received: | September 13, 2005 |
Last Updated: | November 15, 2005 |
ClinicalTrials.gov Identifier: | NCT00164021 History of Changes |
Health Authority: | Australia: Human Research Ethics Committee |
gastroesophageal reflux, gastric reflux, acid reflux, lung transplantation, physiotherapy, anti-reflux medication |
Fibrosis Gastrointestinal Diseases Gastroesophageal Reflux Esophageal Motility Disorders Deglutition Disorders Digestive System Diseases Cystic Fibrosis |
Respiratory Tract Diseases Genetic Diseases, Inborn Esophageal Disorder Lung Diseases Pancreatic Diseases Infant, Newborn, Diseases Esophageal Diseases |
Gastrointestinal Diseases Fibrosis Gastroesophageal Reflux Esophageal Motility Disorders Deglutition Disorders Digestive System Diseases Pathologic Processes |
Cystic Fibrosis Respiratory Tract Diseases Genetic Diseases, Inborn Lung Diseases Pancreatic Diseases Infant, Newborn, Diseases Esophageal Diseases |